New data presented at the American College of Cardiology’s annual meeting, shows that treatment with ticagrelor can significantly reduce the risk of death in acute coronary syndrome patients undergoing heart bypass surgery.
Results from a sub-analysis of the landmark PLATO study, showed that patients randomised to receive the investigational medicine, ticagrelor, had significantly lower rates of mortality than those receiving the current standard of care, clopidogrel (Plavix). The exploratory analysis highlighted that treatment with ticagrelor was associated with: a 51% relative risk reduction in total mortality, 48% reduction in cardiovascular death, and no significant difference in CABG-related major bleeding.
